Indo National Reports FY26 Net Loss of Rs. 1,039.71 Lakh; Board Recommends Rs. 3.75 Dividend

6 min read     Updated on 15 May 2026, 11:02 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Indo National Limited reported audited FY26 results with a standalone net loss of Rs. 1,039.71 lakh against a prior-year profit of Rs. 101.39 lakh, as total expenses rose and income declined. On a consolidated basis, the net loss widened to Rs. 2,669.20 lakh versus a profit of Rs. 12,194.61 lakh in FY25. The Board recommended a final dividend of Rs. 3.75 per share and raised its stake in Medcuore Medical Solutions to 57.48%, while the NCLT-approved amalgamation of Helios Strategic Systems became effective April 2, 2026.

powered bylight_fuzz_icon
40236643

*this image is generated using AI for illustrative purposes only.

Indo National Limited reported audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at its Board meeting held on May 15, 2026. On a standalone basis, the company swung to a net loss of Rs. 1,039.71 lakh for FY26 compared to a net profit of Rs. 101.39 lakh in FY25, weighed down by higher total expenses and a decline in other income. Despite the loss, the Board recommended a final dividend of Rs. 3.75 per share (75%) amounting to Rs. 281.25 lakh on equity shares of Rs. 5 each, subject to shareholder approval. The financial results were audited by M/s. G Balu & Associates LLP, Chartered Accountants, who issued an unmodified audit opinion on both standalone and consolidated results.

Standalone Financial Performance

On a standalone basis, total income declined to Rs. 45,820.77 lakh in FY26 from Rs. 46,662.50 lakh in FY25, driven by a marginal dip in revenue from operations to Rs. 45,100.95 lakh from Rs. 45,797.12 lakh and a fall in other income to Rs. 719.82 lakh from Rs. 865.38 lakh. Total expenses rose to Rs. 46,817.48 lakh from Rs. 46,556.11 lakh, resulting in a loss before tax of Rs. 996.71 lakh against a profit of Rs. 106.39 lakh in the prior year. The standalone earnings per share (basic and diluted) stood at Rs. (13.86) for FY26 versus Rs. 1.35 in FY25.

Key standalone financial metrics are presented below:

Metric: Q4 FY26 (Audited) Q3 FY26 (Unaudited) Q4 FY25 (Audited) FY26 (Audited) FY25 (Audited)
Revenue from Operations (Rs. lakh): 10,638.73 10,611.30 9,710.77 45,100.95 45,797.12
Other Income (Rs. lakh): 151.57 192.24 246.13 719.82 865.38
Total Income (Rs. lakh): 10,790.30 10,803.54 9,956.90 45,820.77 46,662.50
Total Expenses (Rs. lakh): 11,547.33 11,526.49 10,157.92 46,817.48 46,556.11
Profit/(Loss) Before Tax (Rs. lakh): (757.03) (722.95) (201.02) (996.71) 106.39
Net Profit/(Loss) After Tax (Rs. lakh): (808.03) (661.95) (263.02) (1,039.71) 101.39
Total Comprehensive Income (Rs. lakh): (772.28) (654.35) (192.52) (1,023.96) 147.89
EPS – Basic & Diluted (Rs.): (10.77) (8.83) (3.51) (13.86) 1.35

Standalone Balance Sheet Highlights

As at March 31, 2026, standalone total assets stood at Rs. 49,002.09 lakh compared to Rs. 48,747.57 lakh as at March 31, 2025. Equity share capital remained unchanged at Rs. 375.00 lakh, while other equity declined to Rs. 20,835.24 lakh from Rs. 22,234.20 lakh. Total equity stood at Rs. 21,210.24 lakh against Rs. 22,609.20 lakh in the prior year. Current borrowings increased to Rs. 20,144.00 lakh from Rs. 18,725.72 lakh, and cash and cash equivalents improved significantly to Rs. 543.62 lakh from Rs. 29.07 lakh.

Balance Sheet Item: As at 31/03/2026 (Rs. lakh) As at 31/03/2025 (Rs. lakh)
Total Assets: 49,002.09 48,747.57
Equity Share Capital: 375.00 375.00
Other Equity: 20,835.24 22,234.20
Total Equity: 21,210.24 22,609.20
Current Borrowings: 20,144.00 18,725.72
Cash & Cash Equivalents: 543.62 29.07

Consolidated Financial Performance

On a consolidated basis, which includes subsidiaries Helios Strategic Systems Limited, Nippo Green Energy Private Limited, and Medcuore Medical Solutions Private Limited, total income for FY26 stood at Rs. 46,010.46 lakh, significantly lower than Rs. 65,743.86 lakh in FY25, the latter having been boosted by elevated other income. The consolidated net loss for FY26 was Rs. 2,669.20 lakh, compared to a net profit of Rs. 12,194.61 lakh in FY25. Consolidated EPS (basic and diluted) was Rs. (35.12) for FY26 versus Rs. 165.02 in FY25. Total consolidated assets as at March 31, 2026 stood at Rs. 43,066.43 lakh against Rs. 72,147.88 lakh in the prior year.

Metric: Q4 FY26 (Audited) Q3 FY26 (Unaudited) Q4 FY25 (Audited) FY26 (Audited) FY25 (Audited)
Revenue from Operations (Rs. lakh): 10,711.74 10,630.91 9,710.77 45,246.55 46,746.50
Total Income (Rs. lakh): 10,867.49 10,863.06 10,030.65 46,010.46 65,743.86
Total Expenses (Rs. lakh): 12,916.59 11,709.28 10,294.55 48,636.85 50,614.78
Profit/(Loss) Before Tax (Rs. lakh): (2,049.10) (846.22) (263.90) (2,626.39) 15,129.08
Net Profit/(Loss) After Tax (Rs. lakh): (2,099.91) (785.22) 8.19 (2,669.20) 12,194.61
Total Comprehensive Income (Rs. lakh): (2,064.16) (777.62) 78.69 (2,653.45) 12,236.62
EPS – Basic & Diluted (Rs.): (27.87) (10.46) 0.11 (35.12) 165.02

Segment Performance

The Consumer Goods segment, which encompasses the manufacture and sale of dry batteries, trading of lighting products, and other home appliances, remained the primary revenue contributor with FY26 segment revenue of Rs. 45,100.95 lakh. The Air Purifier segment, represented by Medcuore Medical Solutions, contributed Rs. 145.60 lakh in FY26. The Composites & Aerospace segment recorded nil revenue in FY26 following the NCLT-approved amalgamation of Helios Strategic Systems Limited with Indo National Limited, effective April 2, 2026.

Segment: FY26 Revenue (Rs. lakh) FY25 Revenue (Rs. lakh)
Consumer Goods: 45,100.95 45,797.12
Composites & Aerospace: 0.00 949.38
Air Purifier: 145.60 0.00
Investments: 12.56

Medcuore Investment and Other Key Developments

During FY26, Indo National made an additional primary investment of Rs. 80,00,000 in Medcuore Medical Solutions Private Limited (MMSPL) through subscription to 871 equity shares at Rs. 9,187 per share, raising its total shareholding to 57.48% of the paid-up share capital on a fully diluted basis. Cumulatively, the company invested Rs. 693.63 lakh towards acquisition of 54.79% in MMSPL's equity shares, making it a subsidiary. Additionally, Rs. 850 lakh was invested in Compulsory Convertible Preference Shares (CCPS) of Axial Aero Private Limited during the year. The NCLT approved the scheme of amalgamation of Helios Strategic Systems Limited with Indo National Limited vide its order dated March 10, 2026, with the amalgamation becoming effective from April 2, 2026. The Board also re-appointed M/s. B. Thulasiram & Co. as Cost Auditors and M/s. R.G.N. Price & Co. as Internal Auditors, each for a term of one year commencing April 1, 2026.

Investment/Development: Details
Additional Investment in MMSPL: Rs. 80,00,000
Shares Acquired in MMSPL: 871 shares at Rs. 9,187 per share
Total Stake in MMSPL (Post-Acquisition): 57.48%
Cumulative Equity Investment in MMSPL: Rs. 693.63 lakh (54.79% stake)
Investment in Axial Aero (CCPS): Rs. 850 lakh
Helios Amalgamation Effective Date: April 2, 2026
Recommended Dividend: Rs. 3.75 per share (75%) — Rs. 281.25 lakh total

Historical Stock Returns for Indo National

1 Day5 Days1 Month6 Months1 Year5 Years
-1.34%-2.51%-13.47%-14.88%-26.27%-26.67%

How will the NCLT-approved amalgamation of Helios Strategic Systems into Indo National impact the company's revenue mix and profitability in FY27, particularly in the Composites & Aerospace segment?

Given the sharp rise in current borrowings to Rs. 20,144 lakh alongside a net loss of Rs. 1,039.71 lakh, what is Indo National's debt servicing capacity and what refinancing risks could emerge in the near term?

With the Rs. 850 lakh investment in Axial Aero Private Limited's CCPS and a growing stake in Medcuore Medical Solutions, how is Indo National strategically repositioning itself beyond its core dry battery business?

Indo National Limited Schedules Board Meeting on May 15, 2026 to Consider Q4FY26 Audited Results and Dividend

1 min read     Updated on 04 May 2026, 05:00 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Indo National Limited has scheduled a Board of Directors meeting on May 15, 2026, to consider and approve Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended March 31, 2026, along with a dividend recommendation, if any. The intimation was filed on May 4, 2026, by Company Secretary J. Srinivasan, in compliance with Regulation 29 of SEBI LODR Regulations, 2015. The trading window for promoters, directors, connected persons, and designated employees remains closed from April 1, 2026, until 48 hours after the declaration of the audited results. The approved results will be published in newspapers following Board approval.

powered bylight_fuzz_icon
39439806

*this image is generated using AI for illustrative purposes only.

Indo National Limited has informed the stock exchanges of a forthcoming Board of Directors meeting, scheduled for Friday, May 15, 2026, in accordance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed by the company on May 4, 2026, and signed by J. Srinivasan, Company Secretary.

Board Meeting Agenda

The upcoming Board meeting has been convened to consider and approve key financial disclosures. The following matters are on the agenda:

Parameter: Details
Meeting Date: Friday, May 15, 2026
Financial Results: Audited (Standalone & Consolidated)
Period Under Review: Quarter and Year ended March 31, 2026
Additional Agenda: Recommendation of Dividend, if any

The company has also confirmed that the approved Audited Financial Results will be published in newspapers as soon as they are approved and taken on record by the Board at the said meeting.

Trading Window Closure

In line with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Internal Code of Conduct on Prohibition of Insider Trading, the trading window for dealing in the securities of the company has been kept closed. As notified by the company vide its letter dated March 25, 2026, the trading window closure applies to the following categories:

  • Promoters
  • Directors
  • Other connected persons
  • Designated employees of the company

The trading window will remain closed from Wednesday, April 1, 2026, until 48 hours after the declaration of the audited fourth quarter and full-year results of the company.

Regulatory Compliance

The intimation has been filed simultaneously with BSE Limited and the National Stock Exchange of India Ltd., fulfilling the company's disclosure obligations under the applicable SEBI regulations. The company has requested both exchanges to take the information on record.

Historical Stock Returns for Indo National

1 Day5 Days1 Month6 Months1 Year5 Years
-1.34%-2.51%-13.47%-14.88%-26.27%-26.67%

What dividend payout ratio is Indo National likely to recommend given its historical dividend trends and current cash flow position?

How have Indo National's revenue and profitability metrics trended over FY2026 compared to the previous fiscal year, and what could this signal for investor returns?

Will the consolidated financial results reveal any significant divergence from standalone performance, potentially indicating changes in subsidiary contributions or group-level risks?

More News on Indo National

1 Year Returns:-26.27%